Anti-CD20/CD3 Bispecific Monoclonal Antibody RO7082859 Uses, Dosage, Side Effects and more
Anti-CD20/CD3 Bispecific Monoclonal Antibody RO7082859 is under investigation in clinical trial NCT04408638 (A Phase III Study Evaluating Anti-CD20/CD3 Bispecific Monoclonal Antibody RO7082859 in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/refractory Diffuse Large B-cell Lymphoma).
| Trade Name | Anti-CD20/CD3 Bispecific Monoclonal Antibody RO7082859 |
| Generic | Glofitamab |
| Glofitamab Other Names | Anti-CD20/CD3 bispecific monoclonal antibody RO7082859, Glofitamab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
